Supplementary Figures



Supplementary Figure S1: 1st-line PFS experience of the overall study cohort (n=73).



Supplementary Figure S2: OS experience of the overall study cohort (n=74)



Supplementary Figure S3: PFS and OS experience according to treatment assignment to Arm A and Arm B.



Supplementary Figure S4: Cox model based predictions of 1st-line progression-free survival (PFS) according to treatment assignment and CD31 expression. The model fits an interaction between treatment assignment and CD31 expression.



Supplementary Figure S5: Overall survival experience according to CD31+ microvessel density.



Supplementary Figure S6: Immunohistochemical staining of candidate proteins in tissue samples. On the left: representative image of samples with high expression of the respective candidate. On the right: representative image of samples with low expression of the respective candidate. (A) High expression of αV integrin in primary colonic cancer on the left. On the right, expression of αV integrin in tumor surrounding stromal cells (asterisk). Tumor cells showed no expression in this case. (B) Moderate to high expression of NRP1 in primary colonic cancer and in tumor surrounding stromal cells. On the right, expression of NRP1 in tumor surrounding stromal cells (asterisk). Tumor cells showed no to very weak expression in this case. (C) On

the left, high expression of uPAR in primary colonic cancer. On the right, unspecific expression of uPAR in goblet cells. Tumor cells showed no to very weak expression of UPAR. (D) On the left, expression of PTEN in primary colonic cancer. On the right, expression of PTEN in stroma cells.



Supplementary Figure S7: Overall survival experience according to CD98hc status (n=70).



Supplementary Figure S8: Cox model based predictions of 1st-line progression-free survival (PFS) according to treatment assignment and CD98hc status. The model fits an interaction between treatment assignment and CD98hc status.